{"entity":{"id":"nct07226752","kind":"trial","name":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","aka":[],"tldr":"A phase 3 trial of Epcoritamab in diffuse large b-cell lymphoma, run by Genmab, active and no longer recruiting.","summary":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China is a phase 3 interventional study registered as NCT07226752 by Genmab, with 72 participants enrolled, started 2022-10-08 and due to reach its primary completion in 2025-10-13. Interventions recorded: Epcoritamab, Investigator's Choice Chemotherapy. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07226752","url":"https://clinicaltrials.gov/study/NCT07226752"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["epcoritamab"],"companies":["genmab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07226752","phase":"3","setting":"A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","sponsor":"Genmab","enrolled":72,"outcomes":[]},"route":"/trials/nct07226752/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/"}],"company":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"}]}}